eicosapentaenoic acid ethyl ester has been researched along with Hypertriglyceridemia in 77 studies
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the present study was to test whether hyperlipidaemia and insulin resistance in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats can be improved by dietary supplementation with purified eicosapentaenoic acid (EPA) or oleic acid (OA)." | 7.71 | Effect of eicosapentaenoic acid ethyl ester v. oleic acid-rich safflower oil on insulin resistance in type 2 diabetic model rats with hypertriacylglycerolaemia. ( Ishimura, N; Mawatari, K; Minami, A; Nakaya, Y; Okada, K; Sakamoto, S; Takishita, E, 2002) |
| "Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester that has been approved to lower triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia." | 5.69 | Pharmacokinetics of Icosapent Ethyl: An Open-Label, Multiple Oral Dose, Parallel Design Study in Healthy Chinese Subjects. ( Chen, H; Chen, W; Li, H; Li, J; Li, X; Li, Y; Liu, C; Sheng, L; Xu, H; Yang, M; Yuan, F, 2023) |
| "A literature search with keywords Vascepa, icosapent ethyl, AMR101, and eicosapentaenoic acid of articles up to July 2013, along with the package insert for Vascepa and current guidelines for hypertriglyceridemia." | 4.89 | Icosapent ethyl for treatment of elevated triglyceride levels. ( Munger, MA; Nelson, SD, 2013) |
| "The US Food and Drug Administration (FDA) draft guidance for establishing bioequivalence (BE) of ω-3 acid ethyl esters (containing both eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] as ethyl esters), used to treat severe hypertriglyceridemia, recommends the conduct of 2 studies: one with participants in the fasting state and one with participants in the fed state." | 3.85 | Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance. ( Daak, A; Freedman, SD; Harris, WS; Johns, C; Maki, KC; Puder, M; Rabinowicz, AL; Sancilio, FD; Thorsteinsson, T, 2017) |
| "Icosapent ethyl (IPE; Vascepa) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester recently approved in 2012 to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia." | 3.79 | Icosapent ethyl for the treatment of hypertriglyceridemia. ( Ballantyne, CM; Braeckman, RA; Soni, PN, 2013) |
| "The purpose of the present study was to test whether hyperlipidaemia and insulin resistance in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats can be improved by dietary supplementation with purified eicosapentaenoic acid (EPA) or oleic acid (OA)." | 3.71 | Effect of eicosapentaenoic acid ethyl ester v. oleic acid-rich safflower oil on insulin resistance in type 2 diabetic model rats with hypertriacylglycerolaemia. ( Ishimura, N; Mawatari, K; Minami, A; Nakaya, Y; Okada, K; Sakamoto, S; Takishita, E, 2002) |
| "We conducted a long-term comparison of treatment of hypertriglyceridemia with ethyl icosapentate (EPA) vs." | 2.90 | Long-Term Comparison of Ethyl Icosapentate vs. Omega-3-Acid Ethyl in Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial). ( Kanno, S; Obata, K; Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S, 2019) |
| " However, prior medications with triglyceride-lowering effects have not reduced adverse clinical outcomes in the statin era." | 2.82 | Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. ( Bhatt, DL; Mason, RP; Pareek, M, 2022) |
| " OM3CA bioavailability (area under the plasma concentration-time curve from zero to the last measurable concentration) is up to 4-fold greater than that of OM3FA ethyl esters, and unlike ethyl esters, the absorption of OM3CA is not dependent on pancreatic lipase hydrolysis." | 2.53 | The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. ( Anzalone, D; Backes, J; Catini, J; Hilleman, D, 2016) |
| "Hypertriglyceridemia has presented a considerable challenge with regard to understanding its role in the promotion of cardiovascular risk." | 2.52 | Lowering triglycerides to modify cardiovascular risk: will icosapent deliver? ( Nicholls, SJ; Scherer, DJ, 2015) |
| "Congenital generalized lipodystrophy type 4 (CGL4) is a rare autosomal recessive condition with high rates of morbidity and mortality." | 1.72 | Successful treatment of severe hypertriglyceridemia with icosapent ethyl in a case of congenital generalized lipodystrophy type 4. ( Babalola, F; Bulic, A; Curtis, J; Ng, D, 2022) |
| "Hypertriglyceridemia is associated with increased cardiovascular disease (CVD) risk." | 1.62 | Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. ( Baum, S; Bhatt, DL; Boden, WE; Fazio, S; Toth, PP, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.30) | 29.6817 |
| 2010's | 43 (55.84) | 24.3611 |
| 2020's | 33 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Gaba, P | 2 |
| Bhatt, DL | 15 |
| Giugliano, RP | 2 |
| Steg, PG | 9 |
| Miller, M | 11 |
| Brinton, EA | 8 |
| Jacobson, TA | 7 |
| Ketchum, SB | 4 |
| Juliano, RA | 8 |
| Jiao, L | 6 |
| Doyle, RT | 8 |
| Granowitz, C | 5 |
| Tardif, JC | 6 |
| Ballantyne, CM | 15 |
| Pinto, DS | 1 |
| Budoff, MJ | 1 |
| Gibson, CM | 2 |
| Doi, T | 1 |
| Langsted, A | 1 |
| Nordestgaard, BG | 1 |
| Singh, N | 1 |
| Mason, RP | 5 |
| Maki, KC | 2 |
| Bays, HE | 7 |
| Underberg, JA | 1 |
| Kastelein, JJP | 2 |
| Johnson, JB | 1 |
| Ferguson, JJ | 1 |
| Chapman, MJ | 2 |
| Zamorano, JL | 1 |
| Parhofer, KG | 2 |
| Babalola, F | 1 |
| Ng, D | 1 |
| Bulic, A | 1 |
| Curtis, J | 1 |
| Martens, FMAC | 1 |
| Ridker, PM | 1 |
| Rifai, N | 1 |
| MacFadyen, J | 1 |
| Glynn, RJ | 1 |
| Yuan, F | 1 |
| Li, H | 2 |
| Yang, M | 1 |
| Chen, W | 1 |
| Chen, H | 1 |
| Xu, H | 1 |
| Li, J | 1 |
| Sheng, L | 1 |
| Liu, C | 1 |
| Li, Y | 1 |
| Li, X | 1 |
| Tokgozoglu, L | 1 |
| Handelsman, Y | 1 |
| Leiter, LA | 1 |
| Landmesser, U | 1 |
| Catapano, AL | 1 |
| Morton, JI | 1 |
| Liew, D | 1 |
| Nicholls, SJ | 2 |
| Ademi, Z | 1 |
| Wilkins, JT | 1 |
| Lloyd-Jones, DM | 1 |
| Pedro-Botet, J | 3 |
| Barrios, V | 3 |
| Sánchez-Margalet, V | 3 |
| Tamargo, J | 3 |
| Arrieta, F | 3 |
| Gámez, JM | 3 |
| Gimeno-Orna, JA | 3 |
| Escobar, C | 3 |
| Gómez-Doblas, JJ | 3 |
| Pérez, A | 3 |
| Kim, JM | 1 |
| Dagogo-Jack, S | 1 |
| Cherney, DZI | 1 |
| Cosentino, F | 1 |
| McGuire, DK | 1 |
| Pratley, RE | 1 |
| Liu, CC | 1 |
| Cater, NB | 1 |
| Frederich, R | 1 |
| Mancuso, JP | 1 |
| Cannon, CP | 1 |
| Huston, J | 1 |
| Schaffner, H | 1 |
| Cox, A | 1 |
| Sperry, A | 1 |
| Mcgee, S | 1 |
| Lor, P | 1 |
| Langley, L | 1 |
| Skrable, B | 1 |
| Ashchi, M | 1 |
| Bisharat, M | 1 |
| Gore, A | 1 |
| Jones, T | 1 |
| Sutton, D | 1 |
| Sheikh-Ali, M | 1 |
| Berner, J | 1 |
| Goldfaden, R | 1 |
| Wang, Z | 1 |
| Zhang, X | 1 |
| Qu, Y | 1 |
| Zhang, S | 1 |
| Chen, Y | 1 |
| Chen, X | 1 |
| Qi, X | 1 |
| Liu, P | 1 |
| Liu, S | 1 |
| Jiang, S | 1 |
| Man, R | 1 |
| He, L | 1 |
| Wu, L | 1 |
| Li, Z | 1 |
| Shang, Y | 1 |
| Qiu, Z | 1 |
| Liu, F | 1 |
| Xu, C | 1 |
| Lai, C | 1 |
| Ge, J | 1 |
| Di Costanzo, A | 1 |
| Indolfi, C | 1 |
| Sorrentino, S | 1 |
| Esposito, G | 1 |
| Spaccarotella, CAM | 1 |
| Patel, PN | 1 |
| Patel, SM | 1 |
| Boden, WE | 2 |
| Toth, PP | 2 |
| Ray, KK | 1 |
| Lüscher, TF | 1 |
| Spence, JD | 1 |
| Chatterjee, S | 1 |
| Hajra, A | 1 |
| Bandyopadhyay, D | 1 |
| Ghosh, RK | 1 |
| Deedwania, PC | 1 |
| Mosca, L | 3 |
| Navar, AM | 1 |
| Wenger, NK | 1 |
| Hussain, A | 1 |
| Saeed, A | 1 |
| Virani, SS | 1 |
| Trivedi, K | 1 |
| Le, V | 2 |
| Nelson, JR | 3 |
| Bazarbashi, N | 1 |
| Baum, S | 1 |
| Fazio, S | 1 |
| Arbel, R | 1 |
| Aboalhasan, E | 1 |
| Hammerman, A | 1 |
| Azuri, J | 1 |
| Eckel, RH | 1 |
| Budoff, M | 2 |
| Lakshmanan, S | 1 |
| Rodriguez-Granillo, GA | 1 |
| Garcia-Garcia, HM | 1 |
| Pareek, M | 1 |
| Picard, F | 1 |
| Ducrocq, G | 1 |
| Ohman, EM | 1 |
| Goto, S | 1 |
| Eagle, KA | 1 |
| Wilson, PWF | 1 |
| Smith, SC | 1 |
| Elbez, Y | 1 |
| True, WS | 1 |
| Gutstein, AS | 1 |
| Copple, T | 1 |
| Brent Muhlestein, J | 1 |
| Le, VT | 1 |
| May, HT | 1 |
| Roy, S | 1 |
| Guyton, JR | 2 |
| Philip, S | 4 |
| Stroes, ESG | 1 |
| Lim, GB | 1 |
| Gregson, J | 1 |
| Pocock, SJ | 1 |
| Huynh, K | 1 |
| Sezai, A | 1 |
| Unosawa, S | 1 |
| Taoka, M | 1 |
| Osaka, S | 1 |
| Obata, K | 1 |
| Kanno, S | 1 |
| Sekino, H | 1 |
| Tanaka, M | 1 |
| Chan, LN | 1 |
| Borghi, C | 1 |
| Fogacci, F | 1 |
| Cicero, AFG | 1 |
| Doggrell, SA | 1 |
| Lee, M | 1 |
| Ovbiagele, B | 1 |
| Granger, CB | 1 |
| Nelson, AJ | 1 |
| Pagidipati, NJ | 1 |
| Sheikh, O | 1 |
| Vande Hei, AG | 1 |
| Battisha, A | 1 |
| Hammad, T | 1 |
| Pham, S | 1 |
| Chilton, R | 1 |
| Gao, L | 1 |
| Moodie, M | 1 |
| Li, SC | 1 |
| Braeckman, RA | 5 |
| Soni, PN | 5 |
| Manku, MS | 1 |
| Stirtan, WG | 2 |
| Nelson, SD | 1 |
| Munger, MA | 1 |
| Hiatt, WR | 1 |
| Smith, RJ | 1 |
| Castaldo, RS | 1 |
| Tatsuno, I | 1 |
| Weintraub, HS | 1 |
| Kim, ES | 1 |
| McCormack, PL | 1 |
| Caffrey, MK | 1 |
| Scherer, DJ | 1 |
| Kedia, AW | 1 |
| Lynch, E | 1 |
| Hey, SP | 1 |
| Kesselheim, AS | 1 |
| Fialkow, J | 1 |
| Kim, HS | 1 |
| Kim, H | 1 |
| Jeong, YJ | 1 |
| Yang, SJ | 1 |
| Baik, SJ | 1 |
| Lee, H | 1 |
| Lee, SH | 1 |
| Cho, JH | 1 |
| Choi, IY | 1 |
| Yim, HW | 1 |
| Yoon, KH | 1 |
| Backes, J | 1 |
| Anzalone, D | 1 |
| Hilleman, D | 1 |
| Catini, J | 1 |
| Johns, C | 1 |
| Harris, WS | 1 |
| Puder, M | 1 |
| Freedman, SD | 1 |
| Thorsteinsson, T | 1 |
| Daak, A | 1 |
| Rabinowicz, AL | 1 |
| Sancilio, FD | 1 |
| Kastelein, JJ | 2 |
| Isaacsohn, JL | 2 |
| Stein, E | 1 |
| Minami, A | 1 |
| Ishimura, N | 1 |
| Sakamoto, S | 1 |
| Takishita, E | 1 |
| Mawatari, K | 1 |
| Okada, K | 1 |
| Nakaya, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)[NCT01492361] | Phase 3 | 8,179 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Pharmacodynamic Effects of a Free-fatty Acid Formulation of Omega-3 Pentaenoic Acid to ENHANCE Efficacy in Adults With Hypertriglyceridemia: The ENHANCE-IT Trial[NCT04177680] | Phase 2 | 100 participants (Actual) | Interventional | 2020-06-03 | Completed | ||
| Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy[NCT01047501] | Phase 3 | 702 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| The Effect of Ethyl Eicosapentaenoic Acid on Circulating Low-density Lipoproteins and Plasma Lipid Metabolism in Healthy Volunteers[NCT04152291] | 50 participants (Anticipated) | Interventional | 2019-11-12 | Active, not recruiting | |||
| The Icosapent Ethyl and Prevention of Vascular Regenerative Cell Exhaustion Study[NCT04562467] | Phase 4 | 70 participants (Anticipated) | Interventional | 2020-09-24 | Active, not recruiting | ||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL[NCT01047683] | Phase 3 | 229 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 392 |
| Placebo | 507 |
The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 705 |
| Placebo | 901 |
The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 459 |
| Placebo | 606 |
Number of patients with an occurrence of CV death during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 174 |
| Placebo | 213 |
Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 250 |
| Placebo | 355 |
Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 98 |
| Placebo | 134 |
Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 216 |
| Placebo | 321 |
Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 549 |
| Placebo | 690 |
Number of patients with an occurrence of death from any cause during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 274 |
| Placebo | 310 |
Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 108 |
| Placebo | 157 |
Percent change in triglycerides from baseline to end of treatment in the pharmacodynamic population (NCT04177680)
Timeframe: baseline to 28 days
| Intervention | Percent Change from baseline (Median) |
|---|---|
| Omega-3 Pentaenoic Acid (MAT9001) | -20.9 |
| Icosapent Ethyl (Vascepa) | -18.3 |
The percent change from baseline in Omega-3 fatty acid concentrations in the Pharmacodynamic population (NCT04177680)
Timeframe: Baseline to 28 days
| Intervention | Percent Change from baseline (Median) | |||
|---|---|---|---|---|
| Eicosapentaenoic acid (EPA) | Docosahexaenoic acid (DHA) | Docosapentaenoic acid (DPA) | EPA + DHA + DPA | |
| Icosapent Ethyl (Vascepa) | 692 | -3.3 | 140 | 165 |
| Omega-3 Pentaenoic Acid (MAT9001) | 848 | 1.7 | 177 | 205 |
Percent change from baseline in lipoprotein lipids in the per protocol population (NCT04177680)
Timeframe: baseline to 28 days
| Intervention | Percent Change from baseline (Median) | |||||
|---|---|---|---|---|---|---|
| Triglycerides | Total Cholesterol | LDL-Cholesterol | HDL-Cholesterol | VLDL-Cholesterol | Non-HDL-Cholesterol | |
| Icosapent Ethyl (Vascepa) | -15.1 | -3.5 | -2.8 | -1.3 | -10.9 | -4.4 |
| Omega-3 Pentaenoic Acid (MAT9001) | -20 | -5.7 | -4.8 | -2.4 | -15 | -6.9 |
Percent change in other lipoprotein lipids from baseline to end of treatment in the pharmacodynamic population (NCT04177680)
Timeframe: baseline to 28 days
| Intervention | Percent Change from baseline (Median) | ||||
|---|---|---|---|---|---|
| Total Cholesterol | Low density lipoprotein (LDL)-Cholesterol | High density lipoprotein (HDL)-Cholesterol | Very low density lipoprotein (VLDL)-Cholesterol | non-HDL-Cholesterol | |
| Icosapent Ethyl (Vascepa) | -4.1 | -3.1 | -1.1 | -13.3 | -5.2 |
| Omega-3 Pentaenoic Acid (MAT9001) | -5.6 | -4.8 | -1.7 | -15.5 | -7 |
The percent change from baseline in Apolipoproteins, PCSK9 and hs-CRP in the PD Population (NCT04177680)
Timeframe: baseline to 28 days
| Intervention | Percent Change from baseline (Median) | ||||
|---|---|---|---|---|---|
| Apolipoprotein (Apo) A1 | Apo B | Apo C3 | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | High-sensitivity C-reactive protein (hs-CRP) | |
| Icosapent Ethyl (Vascepa) | -3.1 | -2.5 | -11.1 | -7.3 | 8.5 |
| Omega-3 Pentaenoic Acid (MAT9001) | -4 | -3.5 | -12.4 | -6.6 | -5.8 |
Median percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -2.2 |
| Placebo | 7.1 |
Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -1.8 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.8 |
| Placebo | 6.7 |
Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | 1.5 |
| Placebo | 8.8 |
Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -5.0 |
| Placebo | 9.8 |
Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -5.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -17.5 |
| Placebo | 5.9 |
Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.1 |
| Placebo | 15.0 |
Median in percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.1 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -3.8 |
| Placebo | 4.3 |
Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -5.1 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -17.1 |
| Placebo | -2.4 |
Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -2.5 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -4.5 |
| Placebo | -3.0 |
Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 0.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -7.7 |
| Placebo | 7.8 |
Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -7.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -26.6 |
| Placebo | 9.7 |
Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 0.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -19.5 |
| Placebo | 13.7 |
24 reviews available for eicosapentaenoic acid ethyl ester and Hypertriglyceridemia
| Article | Year |
|---|---|
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Eicosapentaenoic Acid; Hea | 2022 |
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Topics: Cardiovascular Diseases; Cholesterol; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Heart Disease Ris | 2022 |
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; | 2023 |
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; E | 2023 |
Cardiovascular risk reduction with icosapent ethyl.
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Lipid | 2019 |
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Humans; Hydroxymethylglut | 2020 |
Defining the Role of Icosapent Ethyl in Clinical Practice.
Topics: Drug Dosage Calculations; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Randomized Controlled | 2020 |
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Apolipoprotein C-III; Atherosclerosis; Eico | 2020 |
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Cost-Benefit Analysis; Cytokines; Ei | 2021 |
Icosapent Ethyl: Niche Drug or for the Masses?
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Pharmaceutical Prepara | 2020 |
Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Eicosapentaenoic Acid; Heart Disease Risk Factors | 2021 |
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
Topics: Adult; Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hypertrig | 2022 |
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Plaqu | 2017 |
Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same.
Topics: Cardiovascular Diseases; Dietary Supplements; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fish Oils | 2017 |
Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Eicosapentaenoic Acid; Humans; Hydroxymethylglutary | 2019 |
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial.
Topics: Atrial Fibrillation; Biomarkers; Cardiovascular Diseases; Dietary Supplements; Down-Regulation; Eico | 2019 |
Isosapent ethyl (Vascepa) for severe hypertriglyceridemia.
Topics: Animals; Clinical Trials as Topic; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Ei | 2013 |
Icosapent ethyl for treatment of elevated triglyceride levels.
Topics: Clinical Trials, Phase III as Topic; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Hypolipide | 2013 |
Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Eicosapentaenoic Acid; Fatty Acids, Omega-3 | 2014 |
Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Topics: Cholesterol, LDL; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Ac | 2014 |
Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
Topics: Administration, Oral; Adult; Animals; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Eicosap | 2014 |
Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Topics: Biomarkers; Cardiovascular Diseases; Down-Regulation; Eicosapentaenoic Acid; Humans; Hypertriglyceri | 2015 |
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Topics: Animals; Cardiovascular Diseases; Chemistry, Pharmaceutical; Cholesterol, LDL; Diet; Dietary Supplem | 2016 |
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Topics: Adult; Biological Availability; Cholesterol, LDL; Diacylglycerol O-Acyltransferase; Docosahexaenoic | 2016 |
18 trials available for eicosapentaenoic acid ethyl ester and Hypertriglyceridemia
| Article | Year |
|---|---|
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
Topics: Aged; Angina, Unstable; Eicosapentaenoic Acid; Endpoint Determination; Female; Humans; Hypertriglyce | 2021 |
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
Topics: Adult; C-Reactive Protein; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Nonesterified; | 2022 |
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
Topics: Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; | 2022 |
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Biomarkers; C-Reactive Protein; Cho | 2022 |
Pharmacokinetics of Icosapent Ethyl: An Open-Label, Multiple Oral Dose, Parallel Design Study in Healthy Chinese Subjects.
Topics: Adult; East Asian People; Eicosapentaenoic Acid; Female; Healthy Volunteers; Humans; Hypertriglyceri | 2023 |
Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.
Topics: Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hyd | 2023 |
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registr
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Myocardial Infarction; | 2021 |
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Biomarkers; Coronary Artery Disease; Disease Progre | 2018 |
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Female; Humans; Hyd | 2018 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Comb | 2019 |
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Topics: Aged; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Hydroxymethylgl | 2019 |
Long-Term Comparison of Ethyl Icosapentate vs. Omega-3-Acid Ethyl in Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial).
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cardiovascular Surgical Proced | 2019 |
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
Topics: Adult; Aged; Apolipoprotein C-III; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Dose-Respo | 2019 |
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Data Interpretation, Statistical | 2016 |
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Data Interpretation, Statistical | 2016 |
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Data Interpretation, Statistical | 2016 |
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Data Interpretation, Statistical | 2016 |
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoprotein C-III; Apolipoproteins B; C-Rea | 2017 |
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoprotein C-III; Apolipoproteins B; C-Rea | 2017 |
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoprotein C-III; Apolipoproteins B; C-Rea | 2017 |
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoprotein C-III; Apolipoproteins B; C-Rea | 2017 |
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
Topics: Body Mass Index; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-C | 2011 |
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Topics: Cardiovascular Diseases; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up Studies; Huma | 2012 |
A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial.
Topics: Adult; Aged; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Eicosapentaeno | 2012 |
35 other studies available for eicosapentaenoic acid ethyl ester and Hypertriglyceridemia
| Article | Year |
|---|---|
Mineral oil and icosapent ethyl may jointly explain the between arm difference of cardiovascular risk in REDUCE-IT.
Topics: Arm; Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hypertrigly | 2021 |
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hydroxymethylglu | 2021 |
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2022 |
Successful treatment of severe hypertriglyceridemia with icosapent ethyl in a case of congenital generalized lipodystrophy type 4.
Topics: Adolescent; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceridemia; Lipodystrophy; Lipodystroph | 2022 |
Should we continue to subsidise therapeutics with uncertain efficacy? Health economic implications for icosapent ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2023 |
Icosapent Ethyl Supplementation and Cardiovascular Prevention-Implications of Evolving Data.
Topics: Cardiovascular Diseases; Dietary Supplements; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2022 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; He | 2023 |
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Heart Di | 2023 |
Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial.
Topics: Biomarkers; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceri | 2019 |
Reduction of cardiovascular risk with icosapent ethyl (Vascepa).
Topics: Cardiovascular Diseases; Drug Administration Schedule; Drug Interactions; Eicosapentaenoic Acid; Hum | 2020 |
Triglyceride lowering drugs: not just icosapent ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Pharmaceutical Prepara | 2020 |
Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
Topics: Aged; Cardiovascular Diseases; Cholesterol, LDL; Eicosapentaenoic Acid; Female; Humans; Hydroxymethy | 2020 |
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
Topics: Adult; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2021 |
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
Topics: Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Eicosapentaenoic Acid; Female; Humans; Hypertr | 2021 |
The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl.
Topics: Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Plaque, Atherosclerotic | 2021 |
Underlying mechanisms involved in the icosapent ethyl reduction of cardiovascular events still cannot be attributed to an anti-atherosclerotic effect.
Topics: Atherosclerosis; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2021 |
FISHing for the Miracle of Eicosapentaenoic Acid.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Risk Factors | 2019 |
Hypertriglyceridaemia - REDUCE-IT with icosapent ethyl.
Topics: Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2019 |
Novel antibody-based reversal agent for ticagrelor.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Platelet Aggregation I | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Risk Factors | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Risk Factors | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl. Reply.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Risk Factors | 2019 |
Effect of icosapent ethyl on stroke risk: Different strokes for different folks?
Topics: Asian People; Cardiovascular Diseases; Eicosapentaenoic Acid; Ethnicity; Humans; Hypertriglyceridemi | 2019 |
Risk of Total Events With Icosapent Ethyl: Can We Reduce It?
Topics: Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2019 |
The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
Topics: Australia; Cardiovascular Diseases; Cost-Benefit Analysis; Delivery of Health Care; Eicosapentaenoic | 2019 |
Icosapent ethyl for the treatment of hypertriglyceridemia.
Topics: Dietary Supplements; Drug Approval; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Hypolipidem | 2013 |
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
Topics: Arachidonic Acid; Cell Membrane; Double-Blind Method; Eicosapentaenoic Acid; Erythrocytes; Female; H | 2013 |
Assessing the clinical benefits of lipid-disorder drugs.
Topics: Cholesterol; Drug Approval; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2014 |
A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
Topics: Aged; Azetidines; Eicosapentaenoic Acid; Esters; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Hy | 2014 |
To treat or not to treat? Questions, controversies in prevention.
Topics: Cardiology; Cardiovascular Diseases; Congresses as Topic; Coronary Disease; Decision Making; Diabete | 2014 |
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Topics: Adult; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Esters; Humans; Hydroxymethy | 2015 |
An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
Topics: Drug Approval; Drug Industry; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Hypolipidemic Age | 2016 |
Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea.
Topics: Disease Management; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Huma | 2016 |
Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
Topics: Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Hy | 2017 |
Effect of eicosapentaenoic acid ethyl ester v. oleic acid-rich safflower oil on insulin resistance in type 2 diabetic model rats with hypertriacylglycerolaemia.
Topics: Abdomen; Adipose Tissue; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dietary Sup | 2002 |